Clinical Trials Logo

Clinical Trial Summary

Part I of this study surveys patients in the Penn Dermatologic Surgery Clinic to evaluate if a need exists for increased patient understanding of their skin history and which factors, if any, related to the patient or their skin history are associated with this need. In part II, the study aim is to evaluate mobile technology as a way of improving patient understanding of diagnoses, treatments, and procedures. In this part of the study, eligible patients from part I will be randomized either to a control group that receives the current standard of care regarding in-clinic counseling, informational handouts, and access to their medical records, or to an intervention group that in addition to the current standard of care, is setup with a mobile app, allowing patients to view a skin history summary report and a reference on their skin findings and procedures. Patients then complete a survey to establish their baseline understanding of their clinic visit. Three weeks later the patient is emailed a follow-up survey to assess their understanding of their in-clinic visit. Differences in understanding between the two study groups will be assessed by comparing the number of correctly answered survey items regarding their in-clinic visit, both at baseline (immediately following their surgery) and three weeks later. Qualitative information regarding satisfaction and areas of improvement will also be collected via survey. Patients who have an appointment during the study period at the Penn Dermatologic Surgery clinic for a skin excision will be eligible for inclusion.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03419637
Study type Interventional
Source University of Pennsylvania
Contact
Status Completed
Phase N/A
Start date April 4, 2017
Completion date December 31, 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT03740815 - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection N/A
Recruiting NCT05779423 - Cryoablation+Ipilimumab+Nivolumab in Melanoma Phase 2
Terminated NCT01468818 - Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma Phase 2
Completed NCT01820234 - Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event N/A
Completed NCT00535769 - Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use Phase 0
Completed NCT00526032 - Melanoma Detection by Oblique-Incidence Optical Spectroscopy N/A
Completed NCT00588341 - Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection Phase 2
Active, not recruiting NCT01447199 - The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
Enrolling by invitation NCT04758988 - AI Augmented Training for Skin Specialists N/A
Not yet recruiting NCT04534868 - Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area N/A
Recruiting NCT04138342 - Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer Phase 1
Completed NCT03673917 - Cosmetology Students and Skin Cancer N/A
Recruiting NCT04341064 - Sun-safe Habits Intervention and Education Phase 3
Completed NCT04206995 - Cancer Sensing: Evaluation of Odour Sampling Techniques
Recruiting NCT05574101 - A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer Phase 2
Not yet recruiting NCT05860881 - Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin) Phase 3
Completed NCT05146622 - Virtual Sun Safe Workplaces Ph I
Recruiting NCT05068310 - Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
Recruiting NCT03889899 - Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia. N/A